Answers are grounded in this paper and cite their sources.
Ablation therapy is emerging as a compelling alternate approach for the management of patients with renal cell carcinoma (RCC), particularly patients who are not surgical candidates. These treatment modalities provide an excellent local control and minimal toxicity, with potential to delay systemic therapy for patients with oligometastatic RCC. This review aims to provide an overview of the role of ablative therapies in the management of patients with localized and oligometastatic RCC.
No takes yet. Share an insight, caveat, or question.
Eid et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: